Ganli Pharmaceutical: Ganjing Insulin Injection Obtains Drug Registration Certificate in UAE

Ganli Pharmaceutical announced that its wholly-owned subsidiary in Europe, Ganli Pharmaceuticals Europe LLC, has received the registration approval from the United Arab Emirates Drug Administration for Basalin insulin glargine injection. The medication is indicated for diabetes, in injectable form with a concentration of 100 units/ml in a 3ml vial. Basalin is a long-acting basal insulin, administered subcutaneously once daily, with a duration of blood sugar lowering effect lasting for 24 hours.